(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Active, not recruiting · NCT05186753 · Registry updated 2026-05-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | Hemic and Lymphatic Diseases, Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, hematologic disorder, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm, superficial spreading melanoma, type III hypersensitivity disease | Active, not recruiting | Phase 2 | 2026-05-22 | NCT05186753 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cogent Biosciences, Inc. | 7 |
57 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.